ReviewBlood2018
How I diagnose and treat venous thromboembolism in sickle cell disease.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis.Annals of hematology · 2022Pooled it
- Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial.Blood advances · 2024Trial
- Comparison of Mortality and Complications After Total Hip Arthroplasty in Patients with Sickle Cell Disease: A Retrospective Match-Controlled Study from TürkiyeTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Targeting PAR1 biased signaling with parmodulin reduces thromboinflammation and acute lung injury in sickle cell disease.Blood advances · 2026Article
- Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.BMC infectious diseases · 2025Article
- Interplay Between Sickle Cell Disease and Thrombosis: A Single Center Experience of Pathophysiology and Potential Risk Factors.Hematology reports · 2025Article
- Hemoglobin C Disease With Splenomegaly and With Factor II Mutation Gene Thrombophilia: A Case Report.Cureus · 2025Article
- Article
- Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.Research and practice in thrombosis and haemostasis · 2024Article
- High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease.JCI insight · 2024Article
- Predisposing Factors and Incidence of Venous Thromboembolism among Hospitalized Patients with Sickle Cell Disease.Journal of clinical medicine · 2023Article
- Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.Blood · 2023Article
- The APC-EPCR-PAR1 axis in sickle cell disease.Frontiers in medicine · 2023Review
- Deep Vein Thrombosis of the Left Lower Limb in a Sudanese Child with Sickle Cell Disease.Medicines (Basel, Switzerland) · 2022Article
- Review
- Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome.Journal of blood medicine · 2021Review
- Total hip arthroplasty for sickle cell osteonecrosis: guidelines for perioperative management.EFORT open reviews · 2020Review
- The molecular basis for the prothrombotic state in sickle cell disease.Haematologica · 2020Article
- Clinical and imaging profiles of pulmonary embolism: a single-institution experience.International journal of emergency medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of venous thromboembolism (VTE) in adult patients with sickle cell disease (SCD) is high. However, overlapping features between the clinical presentation of VTE and SCD complications and a low index of suspicion for thrombosis can influence patient management decisions. VTE in SCD can therefore present management challenges to the clinical hematologist. Herein, we present 3 distinct clinical vignettes that are representative of our clinical practice with SCD patients. These vignettes are discussed with specific reference to the hypercoagulable state in SCD patients, recent VTE diagnosis and anticoagulant therapy guidelines from the general population, and evaluation of the risk of bleeding as a result of long-term exposure to anticoagulant therapy. We examine current diagnostic and treatment options, highlight limitations of the existing clinical prognostic models that offer personalized guidance regarding the duration of anticoagulation, and propose a clinical approach to guide the decision to extend anticoagulation beyond 3 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.